VT-1129

11/01/2018 - "These data support a loading dose-maintenance dose strategy for quickly reaching highly efficacious VT-1129 concentrations for treating cryptococcal meningitis."
11/01/2018 - "In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy."
01/01/2018 - "Our objective was to evaluate the in vivo efficacy of VT-1129 against cryptococcal meningitis. "
11/01/2018 - "Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strategy against cryptococcal meningitis. "
01/01/2018 - "These data demonstrate the potential utility of VT-1129 to have a marked impact in the treatment of cryptococcal meningitis."

01/01/2018 - "To test the in vitro and in vivo efficacy of VT-1161 and VT-1129 in the treatment of oropharyngeal candidiasis with azole-susceptible or -resistant C. "
09/01/2017 - "We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. "

09/01/2017 - "We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. "

11/01/2010 - "Investigational drugs discussed include the chitin synthase inhibitor nikkomycin Z (Valley Fever Solutions/University of Arizona), the glycosylphosphatidylinositol biosynthesis inhibitor E-1210 (Eisai), the β-1,3-d-glucan synthesis inhibitor MK-3118 (Merck & Co/SCYNEXIS), the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals), and the anti-inflammatory nanoemulsion NB-003 (NanoBio)."

01/01/2018 - "VT-1129 reached a significant maximal survival benefit (100%) at a dose of 20 mg/kg of body weight once daily. "